Anti-C9 antibody [53]

• 产品名称

  Anti-C9抗体[53]
  参阅全部 C9 一抗

• 描述

  小鼠单克隆抗体[53] to C9

• 宿主

  Mouse

• 经测试应用

  适用于: ELISA, WB, Flow Cyt, IHC-Pmore details

• 种属反应性

  与反应: Human
  

• 免疫原

  Purified, full length native human complement factor C9 protein.

• 常规说明

  ab17931 recognizes C9 in human serum diluted 1:50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 µg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour).

  
  

  The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.

  If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As

• 形式

  Liquid

• 存放说明

  Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.

• 存储溶液

  pH: 7.40
  Preservative: 0.097% Sodium azide
  Constituents: 0.0268% PBS, 0.754% Sodium chloride

• 浓度

• 批次浓度范围 100 µg 浓度为 1 - 1.15 mg/ml

• 纯度

  Protein G purified

• 纯化说明

  Protein A/G purified.

• Primary antibody说明

  ab17931 recognizes C9 in human serum diluted 1:50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 µg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate.

• 克隆

  单克隆

• 克隆编号

  53

• 骨髓瘤

  Sp2

• 同种型

  IgG1

• 轻链类型

  kappa

The Abpromise guarantee

Abpromise™承诺保证使用ab17931于以下的经测试应用

“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。

• 数据库链接

• Entrez Gene: 735 Human

• Omim: 120940 Human

• SwissProt: P02748 Human

• Unigene: 654443 Human

• 别名

• C9 deficiency with dermatomyositis antibody

• C9D antibody

• CO9_HUMAN antibody

• Complement component 9 antibody

• Complement component 9 deficiency antibody

• Complement component C9 antibody

• Complement component C9b antibody

• ARMD15 antibody

• C9 antibody

• C9 deficiency antibody

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [53] (ab17931)

  Ab17931 staining human normal liver. Staining is localized to the cytoplasm.
  Left panel: with primary antibody at 2 ug/ml. Right panel: isotype control.
  Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 AR buffer, EDTA pH 9.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.

• 

  Flow Cytometry - Anti-C9 antibody [53] (ab17931)

  Overlay histogram showing HeLa cells stained with ab17931 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab17931, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.